Patients with commercial insurance covering AZSTARYS pay no more than $15 per prescription. Even without coverage, no commercially insured patient will pay more than $60 per prescription. *Restrictions apply. See Terms and Conditions. Saving is easy—choose what works best for you! Detailed dosage guidelines and administration information for Azstarys (serdexmethylphenidate and dexmethylphenidate). Includes dose adjustments, warnings and precautions. Azstarys (serdexmethylphenidate/dexmethylphenidate) is commonly used to treat attention deficit hyperactivity disorder (ADHD). Learn more about Azstarys for ADHD. Azstarys may also be used. Azstarys (serdexmethylphenidate / dexmethylphenidate) is a combination stimulant medication that's used for attention deficit-hyperactivity disorder (ADHD). It has two ingredients: serdexmethylphenidate (an extended-release stimulant) and dexmethylphenidate (an immediate-release stimulant). AZSTARYS is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older. AZSTARYS has a high chance for abuse and misuse and may lead to substance use problems, including addiction. Misuse and abuse of AZSTARYS, other methylphenidate containing medicines, and amphetamine containing medicines, can lead to overdose and death. Azstarys (serdexmethylphenidate/dexmethylphenidate) is a prescription drug that’s taken to treat ADHD. The drug comes as an oral capsule that you take once per day. Azstarys is approved for. AZSTARYS is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older. Azstarys may help increase attention and decrease impulsiveness and hyperactivity in people 6 years of age and older with ADHD. It is not known if this medicine is safe and effective in children younger than 6 years of age. Serdexmethylphenidate/dexmethylphenidate, sold under the brand name Azstarys, is a fixed-dose combination medication containing serdexmethylphenidate, a prodrug of dexmethylphenidate, and dexmethylphenidate, a d-threo enantiomer of racemic methylphenidate, which is used to treat attention deficit hyperactivity disorder (ADHD) in people aged six.